Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Bria-OTS |
| Synonyms | |
| Therapy Description |
Bria-OTS comprises a cancer cell line engineered to carry multiple HLA alleles and express a costimulatory molecule (CD80, CD86, or CD40) and immunomodulatory cytokine (GM-CSF, IFNalpha, IL-12, or IL-7), which potentially enhances antitumor immune response (Cancer Res 2023;83(7_Suppl):Abstract nr 685). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Bria-OTS | Bria-OTS comprises a cancer cell line engineered to carry multiple HLA alleles and express a costimulatory molecule (CD80, CD86, or CD40) and immunomodulatory cytokine (GM-CSF, IFNalpha, IL-12, or IL-7), which potentially enhances antitumor immune response (Cancer Res 2023;83(7_Suppl):Abstract nr 685). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06471673 | Phase Ib/II | Bria-OTS Bria-OTS + Cyclophosphamide + Peginterferon alfa-2b + Tislelizumab | A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer | Recruiting | USA | 0 |